In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Large Molecule Future

Executive Summary

In an extraordinary series of deals, Pharma has embraced early-stage large-molecule technology, reflecting both the surging value of biologics and the severity of pipeline anemia. But many observers are skeptical the less experienced Big Pharmas can buy themselves into a brand new business with very different requirements. For start-ups, however, the news is very good--they now have two clear and viable pathways to creating shareholder value: acquisition and alliance.

Related Content

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2008
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Finding a Way Out of Pharma's Dealmaking Dilemma
A Look Back at 2006: The Pipeline Challenge
Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy
The $100 Million IND
Deal Statistics Quarterly, Q2 2006
Amgen/Abgenix: All About a Drug
Know Thy R&D Enemy: The Key to Fighting Attrition


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts